Видео с ютуба Resectable Nsclc

How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans in Resectable NSCLC

Choosing the optimal immunotherapy approach in resectable NSCLC

PERIOPERATIVE TREATMENT APPROACH IN RESECTABLE NSCLC Part 1: A surgeon’s perspective

Neoadjuvant chemo-IO in borderline resectable stage III NSCLC

Multi-Modality Immunotherapy for Resectable Lung Cancer | Dr. Heather Wakelee, Stanford Oncology

Surgery assessment for patients with locally resectable NSCLC

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC

RESECTABLE NSCLC AND THE IMPORTANCE OF GUIDELINE-RECOMMENDED MOLECULAR TESTING

Maximizing the Impact of EGFR-Targeted Therapy in Resectable NSCLC

Integrating Immunotherapy in Resectable NSCLC: From Complexity Toward Clarity

Surgical perspective on neoadjuvant IO for resectable stage III NSCLC

Clinical case review for the definition of resectable NSCLC

LCC Importance of Biomarker Testing in Resectable NSCLC

AACR 2023 highlights on advances in the neoadjuvant treatment of resectable NSCLC with John Heymach

Clinical trials of neoadjuvant targeted therapy in resectable NSCLC

Molecular Testing in Patients With Resectable or Metastatic NSCLC | For the Lung Cancer Nursing Team

Neoadjuvant nivolumab with or without chemotherapy in resectable NSCLC

8 in 8 Series: Biomarker Testing and Neoadjuvant Immunotherapy for Resectable NSCLC

Deciding the best treatment strategy for borderline resectable NSCLC

How to Treat Early Stage Non-Small Cell Lung Cancer in 2025